1673001
Travoprost
United States Pharmacopeia (USP) Reference Standard
Manufacturer: Sigma Aldrich
CAS Number: 157283-68-6
Synonym(S): Travoprost solution
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 3 ML | 1673001-3-ML | In Stock | ₹ 40,756.13 |
1673001 - 3 ML
In Stock
Quantity
1
Base Price: ₹ 40,756.13
GST (18%): ₹ 7,336.103
Total Price: ₹ 48,092.233
grade
pharmaceutical primary standard
API family
travoprost
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
InChI
1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
InChI key
MKPLKVHSHYCHOC-AHTXBMBWSA-N
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
 | Travoprost Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™ | -- | ₹ 19,336.56 | |
| | Sigma Aldrich Fine Chemicals Biosciences Travoprost United States Pharmacopeia (USP) Reference Standard | 157283-68-6 | 3ML | -- | ₹ 45,791.71 | |
| | eMolecules Medchem Express / Travoprost / 1mg / 446273021 / HY-B0584 / / 157283-68-6 / MFCD03411995 / 500.555 / C26H35F3O6 | -- | ₹ 8,312.15 | |
| | Travoprost | -- | ₹ 18,976.23 | |
| | 5-HEPTENOIC ACID, 7-[(1R,2R,3R,5S)-3,5-DIHYDROXY-2-[(1E,3R)-3-HYDROXY-4-[3-(TRIFLUOROMETHYL)PHENOXY]-1-BUTEN-1-YL]CYCLOPENTYL]-, 1-METHYLETHYL ESTER, (5Z)- | -- | ₹ 4,106.88 - ₹ 53,389.44 | |
| | 157283-68-6 | Travoprost | -- | ₹ 5,390.28 - ₹ 62,972.16 |
Related Products
Description
- General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
- Application: Innovative eye drop applications: Travoprost has been incorporated into engineered lipoprotein nanoparticles, showcasing a novel method for drug delivery aimed at enhancing therapeutic efficacy in ocular treatments, particularly for conditions like glaucoma and ocular hypertension (Fukuda et al., 2024).Prostaglandin analogs in glaucoma treatment: The effectiveness and safety of benzalkonium chloride-preserved travoprost eye drops have been critically evaluated, providing insights into their impact on ocular health, particularly on conjunctival goblet cells, which are vital for maintaining eye surface health in glaucoma patients (Nagstrup, 2023).Travoprost liquid nanocrystals: Research into travoprost liquid nanocrystals has demonstrated their potential as a significant advancement in glaucoma therapy, offering improved delivery mechanisms and potentially greater efficacy in reducing intraocular pressure (El-Gendy et al., 2023).Cerebrospinal fluid reabsorption: Studies on prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa reveal new roles for travoprost in physiological processes beyond ocular applications, indicating potential new therapeutic pathways (Pedler et al., 2021).
- Analysis Note: These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
- Other Notes: Sales restrictions may apply.
SAFETY INFORMATION
Pictograms
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2
WGK
WGK 2
Flash Point(F)
55.4 °F
Flash Point(C)
13 °C